FLUOXETINE
Bipolar Depression
Eli Lilly and CompanySmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 81/ 100
Competitive context
28 Active assets in the Bipolar Depression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lurasidone NeuroRx, Inc. | Phase 4 | A |
LITHIUM, ELEMENTAL Dr. Inge Winter | Phase 4 | BBB |
Seroquel® Dr. Inge Winter | Phase 4 | BBB |
LAMOTRIGINE Stony Brook University | Phase 4 | BBB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Joshua Rosenblat | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
FLUOXETINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →